Compare OBDC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBDC | ALKS |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 2015 | 2012 |
| Metric | OBDC | ALKS |
|---|---|---|
| Price | $11.35 | $33.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $14.28 | ★ $43.43 |
| AVG Volume (30 Days) | ★ 5.6M | 2.7M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 13.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.24 | ★ 1.43 |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | N/A | $24.26 |
| Revenue Next Year | N/A | $4.63 |
| P/E Ratio | ★ $8.80 | $23.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.52 | $25.17 |
| 52 Week High | $15.19 | $36.48 |
| Indicator | OBDC | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 59.47 |
| Support Level | $11.07 | $26.80 |
| Resistance Level | $11.69 | $35.46 |
| Average True Range (ATR) | 0.32 | 1.41 |
| MACD | 0.04 | 0.28 |
| Stochastic Oscillator | 90.76 | 67.14 |
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.